Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_3
5
71%
Ph phase_2
1
14%

Phase Distribution

1

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
5(71.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Terminated3
Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 35 (71.4%)

Trials by Status

terminated343%
withdrawn114%
completed343%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_1

The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

NCT01881958
completedphase_3

Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

NCT00615264
completedphase_3

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

NCT01103284
terminatedphase_3

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

NCT01898286
terminatedphase_3

OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

NCT01460251
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01881958Phase 1

The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

Withdrawn
NCT00615264Phase 3

Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Completed
NCT01103284Phase 3

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

Completed
NCT01898286Phase 3

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

Terminated
NCT01460251Phase 3

OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

Terminated
NCT00644501Phase 3

Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes

Completed
NCT00058981Phase 2

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7